Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer.

In a previous small series of surgically treated non-small cell lung cancer patients (NSCLC), we found that higher apoptotic index (AI) negatively influenced survival (Dworakowska D, Jassem E, Jassem J, Karmolinski A, Dworakowski R, Wirth T, et al. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. J Cancer Res Clin Oncol 2005; 131:617-623.). In this study we attempted to verify our previous finding in larger group of 170 NSCLC cases, additionally correlating AI to selected cell cycle regulators as well as a proliferation marker. Apoptosis was assessed with the use of the TUNEL technique, whereas the expression of p53, pRb, mdm2, p21(WAF1/CIP1), cyclin D1 and PCNA were assessed immunohistochemically. The mean and the median AI was 12 and 8, respectively. The expression of p53, pRb, mdm2, p21(WAF1/CIP1) proteins and cyclin D1 was found in 47%, 71%, 37%, 65% and 40% of cases, respectively. The mean and the median PCNA labeling index (PCNA LI) was 34 and 35, respectively. AI was not correlated with any patient characteristic or other tumor markers. In uni- and multivariate analysis AI, analysed separately or jointly with cell cycle regulators and PCNA LI, did not influence disease-free or over-all survival. However, patients with "very high AI/very high PCNA LI" had a particularly poor prognosis (P=0.001). Patients with "very low AI/negative pRb" phenotype survived for a shorter time in comparison to others (P=0.04). In addition, patients with the highest PCNA LI had a worse outcome in comparison to patients with the lowest PCNA LI (P=0.04), especially those with concomitant p53 protein expression (P=0.026) or lacking pRb protein expression (P=0.04). This study demonstrates that joint analysis of several factors involved in apoptosis, proliferation and cell cycle regulation, but not AI alone, might provide additional prognostic information in NSCLC patients.

[1]  J. Jassem,et al.  Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  A. Marchetti,et al.  mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[3]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[4]  H. Wada,et al.  Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Roninson.  Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. , 2002, Cancer letters.

[6]  S. Ylä-Herttuala,et al.  False-positive apoptosis signal in mouse kidney and liver detected with TUNEL assay , 2000, Apoptosis.

[7]  H. Wada,et al.  Apoptotic tumor-cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancer. , 2002, Lung cancer.

[8]  M. Haniuda,et al.  Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in resected non-small-cell lung cancers , 2002, International Journal of Clinical Oncology.

[9]  F. Puglisi,et al.  Balance between Cell Division and Cell Death as Predictor of Survival in Patients with Non-Small-Cell Lung Cancer , 2002, Oncology.

[10]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[11]  E. Brambilla,et al.  Alterations of expression of Rb, p16INK4A and cyclin D1 in non‐small cell lung carcinoma and their clinical significance , 1999, The Journal of pathology.

[12]  D. Vaux,et al.  Apoptosis in the development and treatment of cancer. , 2004, Carcinogenesis.

[13]  J. Pignon,et al.  Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[15]  J. Bartek,et al.  Cyclin D1 expression is regulated by the retinoblastoma protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Yap,et al.  mdm2: a bridge over the two tumour suppressors, p53 and Rb , 1999, Oncogene.

[17]  J. Jassem,et al.  Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC) , 2005, Journal of Cancer Research and Clinical Oncology.

[18]  J. Jassem,et al.  Absence of prognostic significance of p21WAF1/CIP1 protein expression in non-small cell lung cancer , 2005, Acta oncologica.

[19]  M. Kris,et al.  Non-small cell lung cancer. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[21]  Y. Soini,et al.  Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. , 1995, Cancer research.

[22]  J. Jassem,et al.  Prognostic Relevance of Altered pRb and p53 Protein Expression in Surgically Treated Non-Small Cell Lung Cancer Patients , 2004, Oncology.

[23]  A. Marchetti,et al.  Cyclin D1 and retinoblastoma susceptibility gene alterations in non‐small cell lung cancer , 1998, International journal of cancer.

[24]  A. Gazdar,et al.  Apoptosis and lung cancer: A review , 2003, Journal of cellular biochemistry.

[25]  R. Dziadziuszko,et al.  Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. , 2000, The Journal of thoracic and cardiovascular surgery.

[26]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[27]  G. Strauss.  Prognostic markers in resectable non-small cell lung cancer. , 1997, Hematology/oncology clinics of North America.

[28]  Women and lung cancer: waiting to exhale. , 1997, Chest.

[29]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[30]  N. Aaronson,et al.  The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  Oliver Gautschi,et al.  Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. , 2007, Lung cancer.

[32]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[33]  M. Borner,et al.  p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. , 2000, International journal of oncology.

[34]  R. Dziadziuszko,et al.  MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). , 2004, Lung cancer.

[35]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[36]  J. Bartek,et al.  DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 , 1994, The Journal of cell biology.

[37]  J. Jassem,et al.  Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. , 2002, Lung cancer.